CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients

Trial Details

NCT ID

NCT05994690

Phase

PHASE3

Sponsor

Princess Maxima Center for Pediatric Oncology

Status

RECRUITING

Cancer Type

Leukemia

Interventions

• Standard Intervention Rc
• Investigational Intervention Rc
• Standard Intervention Ri
• Investigational Intervention Ri

Locations (sample)

• Utrecht, Utrecht, Netherlands|52.09083,5.12222

Key Eligibility Criteria

• Patients are eligible for the study if they fulfil all four criteria below:
• Newly diagnosed AML as defined by the diagnostic criteria in section 8.1. Note that different blast thresholds may apply for different genetic abno…
• Age ≥ day and ≤18 years old at initial diagnosis.
• Written informed consent/assent from patients and/or from parents or legal guardians for minor patients, according to local law and regulations. In…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.